secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001609550-24-000036
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system
--------------------------------------------------------------------------------

- FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.
- Targets soft launch in late 2024 and full commercial launch in 2025.
- Company focusing on operational readiness: product manufacturing and inventory levels for U.S. launch.
- CEO cites FDA approval as a key milestone for Inspire therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000036/0001609550-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955024000036/insp-20240802.htm
  HTML page:      https://secwatch.observer/filing/0001609550-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer